Sequential EGFR inhibition sensitizes glioblastoma to temozolomide.

Glioblastoma (GBM) remains a devastating disease for which standard temozolomide chemotherapy is limited by O6-methylguanine-DNA methyltransferase (MGMT)-mediated DNA damage repair. By targeting epidermal growth factor receptor (EGFR), a major oncogenic driver of GBM, Guo, Habib, and colleagues demonstrate that EGFR inhibition prior to temozolomide treatment induces an adaptive response that downregulates MGMT, enhancing therapeutic efficacy.